

SUPPLEMENTAL TABLE S1:

Grading criteria used for transfusion-related adverse events in PLADO, based on Common Toxicity Criteria for Adverse Events v3.0. All events on this list were to be reported if they occurred during or within 4 hours after the end of a transfusion, whether or not the event was judged to be caused by the transfusion.

<i>EVENT</i>	GRADE				
	0		2	3	4
B5. Allergic reaction/ Hypersensitivity	<input type="checkbox"/> ₀ None	<input type="checkbox"/> ₁ transient flushing or rash	<input type="checkbox"/> ₂ rash, flushing, urticaria, dyspnea	<input type="checkbox"/> ₃ symptomatic bronchospasm, with or without urticaria; parenteral medication(s), indicated; allergy-related edema/ angioedema, hypotension	<input type="checkbox"/> ₄ anaphylaxis
B6. Sinus bradycardia	<input type="checkbox"/> ₀ None	<input type="checkbox"/> ₁ asymptomatic, intervention not indicated	<input type="checkbox"/> ₂ non-urgent medical intervention indicated	<input type="checkbox"/> ₃ symptomatic and incompletely controlled medically, or controlled with device (e.g. pacemaker)	<input type="checkbox"/> ₄ life-threatening (e.g. arrhythmia associated with CHF, hypotension syncope, shock)
B7. Sinus tachycardia	<input type="checkbox"/> ₀ None	<input type="checkbox"/> ₁ asymptomatic, intervention not indicated	<input type="checkbox"/> ₂ non-urgent medical intervention indicated	<input type="checkbox"/> ₃ symptomatic and incompletely controlled medically, or controlled with device (e.g. pacemaker)	<input type="checkbox"/> ₄ life-threatening (e.g. arrhythmia associated with CHF, hypotension syncope, shock)

Table S1 continues on next page

Table S1, continued

EVENT	GRADE				
	0		2	3	4
B8. Hypertension	<input type="checkbox"/> ₀ None	<input type="checkbox"/> ₁ asymptomatic, transient (<24hrs) increase by >20mmHg (diastolic) or to >150/100* if previously WNL; intervention not indicated	<input type="checkbox"/> ₂ recurrent or persistent (>24hrs) symptomatic increase by >20mmHg (diastolic) or to >150/100* if previously WNL; monotherapy may be indicated	<input type="checkbox"/> ₃ requiring more than one drug or more intensive therapy than previously	<input type="checkbox"/> ₄ Life-threatening consequences (e.g.hypertensive crisis)
<i>*Note: For pediatric patients, use age and sex appropriate normal values > 95th percentile ULN.</i>					
B9. Hypotension	<input type="checkbox"/> ₀ None	<input type="checkbox"/> ₁ changes, intervention not indicated	<input type="checkbox"/> ₂ brief (<24hrs) fluid replacement or other therapy; no physiologic consequences	<input type="checkbox"/> ₃ sustained (≥24hrs) therapy, resolves without persisting physiologic consequences	<input type="checkbox"/> ₄ shock (acidemia; impairment of vital organ function)
B10. Dyspnea (shortness of breath)	<input type="checkbox"/> ₀ Normal	<input type="checkbox"/> ₁ dyspnea on exertion, but can walk 1 flight of stairs without stopping	<input type="checkbox"/> ₂ dyspnea on exertion but unable to walk 1 flight of stairs or 1 city block (0.1km) without stopping	<input type="checkbox"/> ₃ dyspnea with ADL	<input type="checkbox"/> ₄ dyspnea at rest; intubation/ventilator indicated
B11. Hypoxia	<input type="checkbox"/> ₀ Normal	—	<input type="checkbox"/> ₂ decreased O ₂ saturation with exercise (e.g. pulse oximeter<88%); intermittent supplemental oxygen	<input type="checkbox"/> ₃ decreased O ₂ saturation at rest; continuous oxygen indicated	<input type="checkbox"/> ₄ life-threatening; intubation or ventilation indicated
B12. Wheezing	<input type="checkbox"/> ₀ None	<input type="checkbox"/> ₁ asymptomatic	<input type="checkbox"/> ₂ symptomatic not interfering with function	<input type="checkbox"/> ₃ symptomatic interfering with function	<input type="checkbox"/> ₄ life-threatening
B13. Cough	<input type="checkbox"/> ₀ None	<input type="checkbox"/> ₁ symptomatic, non-narcotic medication only indicated	<input type="checkbox"/> ₂ symptomatic and narcotic medication indicated	<input type="checkbox"/> ₃ Operative intervention indicated	<input type="checkbox"/> ₄ life-threatening (e.g. hemodynamic instability or ventilatory support indicated)

Table S1 continues on next page

Table S1, continued

EVENT	GRADE				
	0		2	3	4
B14. Hemolysis	<input type="checkbox"/> ₀ None	<input type="checkbox"/> ₁ laboratory evidence of hemolysis only (direct antiglobulin test [DAT, Coombs'] schistocytes)	<input type="checkbox"/> ₂ evidence of red cell destruction and ≥ 2 gm decrease in hemoglobin, no transfusion	<input type="checkbox"/> ₃ transfusion or medical intervention (e.g. steroids) indicated	<input type="checkbox"/> ₄ catastrophic consequences of hemolysis (e.g. renal failure, hypotension, bronchospasm)
B15. Rigors, chills	<input type="checkbox"/> ₀ None	<input type="checkbox"/> ₁ mild requiring symptomatic treatment (e.g., blanket) or non-narcotic medication	<input type="checkbox"/> ₂ severe and/or prolonged, requiring narcotic medication	<input type="checkbox"/> ₃ not responsive to narcotic medication	—
B16. Fever	<input type="checkbox"/> ₀ None	<input type="checkbox"/> ₁ 38.0 – 39.0°C (100.4 – 102.2°F)	<input type="checkbox"/> ₂ >39.0 – 40.0°C (>102.2 – 104.0°F)	<input type="checkbox"/> ₃ >40.0°C (>104.0°F) for ≤ 24 hours	<input type="checkbox"/> ₄ >40.0°C (>104.0°F) for >24 hours
<i>Note: The temperature measurements listed above are oral or tympanic</i>					
B17. Infection	<input type="checkbox"/> ₀ None	—	<input type="checkbox"/> ₂ localized, local intervention indicated	<input type="checkbox"/> ₃ IV antibiotic, antifungal, or antiviral intervention indicated, interventional radiology or operative intervention indicated	<input type="checkbox"/> ₄ life-threatening consequences (e.g. septic shock, hypotension, acidosis, necrosis)